Article

Defining and targeting adaptations to oncogenic KRAS <sup>G12C</sup> inhibition using quantitative temporal proteomics

2019-09-14

Abstract excerpt

<h4>ABSTRACT</h4> Covalent inhibitors of the KRAS G12C oncoprotein have recently been developed and are being evaluated in clinical trials. Resistance to targeted therapies is common and likely to limit long-term efficacy of KRAS inhibitors (KRASi). To identify pathways of adaptation to KRASi and to predict drug combinations that circumvent resistance, we used a mass spectrometry-based quantitative temporal prot...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: aab0a74a-9dac-527a-b04f-fe9656a02df6
DOI: 10.1101/769703

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Defining and targeting adaptations to oncogenic KRAS <sup>G12C</sup> inhibition using quantitative temporal proteomicsDOI 10.1101/769703Read

Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics.Semantic proximity Read

Cell Type-specific Adaptive Signaling Responses to KRASG12C Inhibition.Semantic proximity Read

Addicted to proteostasis: How KRAS-driven cancers acquire resistance to clinical KRAS inhibitors.Semantic proximity Read

Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of SotorasibSemantic proximity Read

Oncogenic mutations of KRAS modulate its turnover by the CUL3/LZTR1 E3 ligase complex.Semantic proximity Read

Discovery of highly potent and selective KRASG12C degraders by VHL-recruiting PROTACs for the treatment of tumors with KRASG12C-Mutation.Semantic proximity Read

SHP2 Inhibition Abrogates Adaptive Resistance to KRAS <sup>G12C</sup> -Inhibition and Remodels the Tumor Microenvironment of <i>KRAS</i> -Mutant TumorsSemantic proximity Read

Next batter up! Targeting cancers with KRAS-G12D mutations.Semantic proximity Read

Interplay Between KRAS and LZTR1 Protein Turnover, Controlled by CUL3/LZTR1 E3 Ubiquitin Ligase, is Disrupted by KRAS MutationsSemantic proximity Read

Integrated multi-omics characterization of KRAS mutant colorectal cancer.Semantic proximity Read

Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers.Semantic proximity Read

Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in CRCSemantic proximity Read